| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
This compound does not possess a specific biological target; its primary function is as a specialized building block for peptide synthesis. As a pseudoproline dipeptide, it is used to overcome aggregation and enhance peptide quality in Fmoc SPPS for peptides containing the Gly-Thr dipeptide motif. The pseudoproline modification reversibly protects the Thr residue and disrupts β-sheet formation during synthesis.
|
|---|---|
| ln Vitro |
This compound is not a biological agent and does not exhibit direct in vitro biological activity in a pharmacological sense. Its value lies in its chemical utility as a specialized building block for improving peptide synthesis efficiency.
|
| ln Vivo |
Fmoc-Gly-Thr(psi(Me,Me)pro)-OH is not administered in vivo as a therapeutic agent. It is a research chemical utilized as a building block in peptide synthesis. The final deprotected peptide product, not this protected intermediate, would be the subject of in vivo pharmacological testing for therapeutic efficacy and safety.
|
| Enzyme Assay |
Non-cellular enzyme/receptor binding assays are not applicable to this compound as it is not biologically active. Its use is in peptide synthesis. A typical protocol involves its use as a building block in Fmoc SPPS to introduce the Gly-Thr dipeptide motif while suppressing aggregation. The pseudoproline is stable during chain assembly and can be removed under TFA treatment during final cleavage.
|
| Cell Assay |
This compound is not used in cell-based assays as a therapeutic agent. Its role is as a research chemical and building block for peptide synthesis. It should be stored at -20°C. It is a solid. Purity is typically high. The product is for research purposes only and is not intended for human or veterinary use.
|
| Animal Protocol |
In vivo animal experiments do not involve this compound as a test article. It is a chemical intermediate used in the synthesis of peptide-based drug candidates. If used to synthesize a therapeutic peptide, that final product would be subjected to animal testing. The pseudoproline dipeptide itself is not administered to animals as a therapeutic agent.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not applicable to this compound as it is not a drug. It is a small molecule (MW 468.50 g/mol). Its properties are relevant for chemical handling and storage rather than for systemic exposure studies. The pseudoproline modification is acid-labile and removed during final peptide cleavage.
|
| Toxicity/Toxicokinetics |
The toxicity of this compound is not extensively documented, as it is a research chemical not intended for human or veterinary use. It should be handled with standard laboratory precautions, including the use of appropriate personal protective equipment and working in a well-ventilated area.
|
| References |
[1]. Yuankun Dao, et al. α-Selective Lysine Ligation and Application in Chemical Synthesis of Interferon Gamma. Org Lett. 2019 May 3;21(9):3265-3270.
|
| Additional Infomation |
Fmoc-Gly-Thr(psi(Me,Me)pro)-OH is a pseudoproline dipeptide used as a tool for overcoming aggregation and enhancing peptide quality in Fmoc SPPS. Pseudoproline technology is widely used to improve the synthesis of difficult peptide sequences. It is not a pharmaceutical.
|
| Molecular Formula |
C24H26N2O6
|
|---|---|
| Molecular Weight |
438.47
|
| Exact Mass |
438.179
|
| CAS # |
1262308-49-5
|
| PubChem CID |
73506419
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.29
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
32
|
| Complexity |
718
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C[C@@H]1[C@H](N(C(O1)(C)C)C(=O)CNC(=O)OCC2C3=CC=CC=C3C4=CC=CC=C24)C(=O)O
|
| InChi Key |
NUXZZZZUNKUMGM-SZNDQCEHSA-N
|
| InChi Code |
InChI=1S/C24H26N2O6/c1-14-21(22(28)29)26(24(2,3)32-14)20(27)12-25-23(30)31-13-19-17-10-6-4-8-15(17)16-9-5-7-11-18(16)19/h4-11,14,19,21H,12-13H2,1-3H3,(H,25,30)(H,28,29)/t14-,21+/m1/s1
|
| Chemical Name |
(4S,5R)-3-[2-(9H-fluoren-9-ylmethoxycarbonylamino)acetyl]-2,2,5-trimethyl-1,3-oxazolidine-4-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 250 mg/mL (570.16 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.74 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.74 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.74 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2807 mL | 11.4033 mL | 22.8066 mL | |
| 5 mM | 0.4561 mL | 2.2807 mL | 4.5613 mL | |
| 10 mM | 0.2281 mL | 1.1403 mL | 2.2807 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
